RxDoctor Payments Data

Victor Zaragoza

Family · McAllen, TXNPI 1518685262

Payments from drug & device makers

$1,745in general payments, 2019–2025

Across 97 payments — averaging $17.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$398
  • Lilly USA, LLC$377
  • Astellas Pharma US Inc$139
  • Johnson & Johnson$134
  • GSK$82
  • Exact Sciences$74
  • plus $541 from 13 others

What the payments were for

  • Food & beverage$1,63294%
  • Education$1136%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,745 in reported general payments places this provider in the 75th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide90$93,762
JanuviaSitagliptin Phosphate27$33,588
LinzessLinaclotide33$26,704
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$19,483
Tresiba Flextouch U-200Insulin Degludec23$18,554
JardianceEmpagliflozin13$17,765
JanumetSitagliptin Phos/Metformin Hcl14$17,533
FarxigaDapagliflozin Propanediol21$15,541
RybelsusSemaglutide14$15,411
TradjentaLinagliptin17$11,271
MyrbetriqMirabegron17$11,060
VascepaIcosapent Ethyl11$5,333
Dexlansoprazole DrDexlansoprazole14$2,999
Diclofenac Sodium59$1,949
Ammonium Lactate45$1,293

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$398$109,173104 claims
Boehringer IngelheimJardiance, Tradjenta$48$29,03630 claims
AbbVieLinzess$53$26,70433 claims
GSKTrelegy Ellipta$82$19,48328 claims
AstraZenecaFarxiga$52$15,54121 claims
Astellas Pharma US IncMyrbetriq$139$11,06017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 15,456 family providers in Texas.

Other family in McAllen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →